Lantidra’s First-Cycle Complete Response Letter Centered On Inspection And Product Quality Issues

 
• By Sue Sutter
Drug Review Profile: Lantidra
CellTrans had to address a host of product quality deficiencies before approval. • Source: Pink Sheet/Shutterstock

More from Drug Review Profiles

More from Product Reviews